Multiple myelomaReferences


This evidence summary was written by:

William B. Grant, Ph.D.
Sunlight, Nutrition, and Health Research Center (SUNARC)
P.O. Box 641603
San Francisco, CA
[email protected]

Last updated

June 2011


Page last edited: 18 July 2011


  1. Badros, A. Goloubeva, O. Terpos, E. Milliron, T. Baer, M. R. Streeten, E. Prevalence and significance of vitamin D deficiency in multiple myeloma patients. Br J Haematol. 2008 Jul; 142 (3): 492-4.
  2. Barille, S. Akhoundi, C. Collette, M. Mellerin, M. P. Rapp, M. J. Harousseau, J. L. Bataille, R. Amiot, M. Metalloproteinases in multiple myeloma: production of matrix metalloproteinase-9 (MMP-9), activation of proMMP-2, and induction of MMP-1 by myeloma cells. Blood. 1997 Aug 15; 90 (4): 1649-55.
  3. Barille, S. Collette, M. Bataille, R. Amiot, M. Myeloma cells upregulate interleukin-6 secretion in osteoblastic cells through cell-to-cell contact but downregulate osteocalcin. Blood. 1995 Oct 15; 86 (8): 3151-9.
  4. Becker, N. Epidemiology of multiple myeloma. Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer. 2011; 18325-35.
  5. Boscoe, F. P. Schymura, M. J. Solar ultraviolet-B exposure and cancer incidence and mortality in the United States, 1993-2002. BMC Cancer. 2006; 6264.
  6. Chang, E. T. Canchola, A. J. Cockburn, M. Lu, Y. Wang, S. S. Bernstein, L. Clarke, C. A. Horn-Ross, P. L. Adulthood residential ultraviolet radiation, sun sensitivity, dietary vitamin D, and risk of lymphoid malignancies in the California Teachers Study. Blood. 2011 May 26;
  7. Diamond, T. Golombick, T. Manoharan, A. Vitamin D status may effect the skeletal complications of multiple myeloma. Am J Hematol. 2010 Apr; 85 (4): 302-3.
  8. Grant, W. B. Ecologic studies of solar UV-B radiation and cancer mortality rates. Recent Results Cancer Res. 2003; 164371-7.
  9. Grant, W. B. An ecologic study of cancer mortality rates in Spain with respect to indices of solar UVB irradiance and smoking. Int J Cancer. 2007 Mar 1; 120 (5): 1123-8.
  10. Grant, W. B. Effect of interval between serum draw and follow-up period on relative risk of cancer incidence with respect to 25-hydroxyvitamin D level; implications for meta-analyses and setting vitamin D guidelines. Dermato-endocrinology. 2011; 3 (3):
  11. Holick, M. F. Multiple myeloma and cancer: is there a D-lightful connection?. Am J Hematol. 2009 Jul; 84 (7): 393-4.
  12. Hosgood, H. D., 3rd Baris, D. Zahm, S. H. Zheng, T. Cross, A. J. Diet and risk of multiple myeloma in Connecticut women. Cancer Causes Control. 2007 Dec; 18 (10): 1065-76.
  13. Imseis, R. E. Palmieri, G. M. Holbert, J. M. Leventhal, M. R. Sebes, J. I. Effect of calcitriol and pamidronate in multiple myeloma. Am J Med Sci. 1999 Jul; 318 (1): 61-6.
  14. Jezierska, A. Motyl, T. Matrix metalloproteinase-2 involvement in breast cancer progression: a mini-review. Medical science monitor : international medical journal of experimental and clinical research. 2009 Feb; 15 (2): RA32-40.
  15. Khuder, S. A. Mutgi, A. B. Meta-analyses of multiple myeloma and farming. Am J Ind Med. 1997 Nov; 32 (5): 510-6.
  16. Laroche, M. Lemaire, O. Attal, M. Vitamin D deficiency does not alter biochemical markers of bone metabolism before or after autograft in patients with multiple myeloma. Eur J Haematol. 2010 Jul; 85 (1): 65-7.
  17. Lawson-Matthew, P. Clayton, J. Guilland-Cumming, D. Yates, A. Preston, E. Greaves, M. Kanis, J. A. Vitamin D metabolism in myeloma. Br J Haematol. 1989 Sep; 73 (1): 57-60.
  18. Lim, U. Freedman, D. M. Hollis, B. W. Horst, R. L. Purdue, M. P. Chatterjee, N. Weinstein, S. J. Morton, L. M. Schatzkin, A. Virtamo, J. Linet, M. S. Hartge, P. Albanes, D. A prospective investigation of serum 25-hydroxyvitamin D and risk of lymphoid cancers. Int J Cancer. 2009 Feb 15; 124 (4): 979-86.
  19. Mahindra, A. Cirstea, D. Raje, N. Novel therapeutic targets for multiple myeloma. Future oncology. 2010 Mar; 6 (3): 407-18.
  20. Mahindra, A. Cirstea, D. Raje, N. Novel therapeutic targets for multiple myeloma. Future oncology. 2010 Mar; 6 (3): 407-18.
  21. Ng, A. C. Kumar, S. K. Rajkumar, S. V. Drake, M. T. Impact of vitamin D deficiency on the clinical presentation and prognosis of patients with newly diagnosed multiple myeloma. Am J Hematol. 2009 Jul; 84 (7): 397-400.
  22. Paduch, R. Kandefer-Szerszen, M. Vitamin D, tamoxifen and beta-estradiol modulate breast cancer cell growth and interleukin-6 and metalloproteinase-2 production in three-dimensional co-cultures of tumor cell spheroids with endothelium. Cell Biol Toxicol. 2005 Sep-Nov; 21 (5-6): 247-56.
  23. Papapetrou, P. D. Bergi-Stamatelou, M. Karga, H. Thanou, S. Hypercalcemia due to sun exposure in a patient with multiple myeloma and elevated parathyroid hormone-related protein. Eur J Endocrinol. 2003 Mar; 148 (3): 351-5.
  24. Robien, K. Cutler, G. J. Lazovich, D. Vitamin D intake and breast cancer risk in postmenopausal women: the Iowa Women's Health Study. Cancer causes & control : CCC. 2007 Sep; 18 (7): 775-82.
  25. Segarra, M. Lozano, E. Corbera-Bellalta, M. Vilardell, C. Cibeira, M. T. Esparza, J. Izco, N. Blade, J. Cid, M. C. Thalidomide decreases gelatinase production by malignant B lymphoid cell lines through disruption of multiple integrin-mediated signaling pathways. Haematologica. 2010 Mar; 95 (3): 456-63.
  26. Tokar, E. J. Webber, M. M. Cholecalciferol (vitamin D3) inhibits growth and invasion by up-regulating nuclear receptors and 25-hydroxylase (CYP27A1) in human prostate cancer cells. Clin Exp Metastasis. 2005; 22 (3): 275-84.
  27. Waxman, A. J. Mink, P. J. Devesa, S. S. Anderson, W. F. Weiss, B. M. Kristinsson, S. Y. McGlynn, K. A. Landgren, O. Racial disparities in incidence and outcome in multiple myeloma: a population-based study. Blood. 2010 Dec 16; 116 (25): 5501-6.
  28. Wigington, D. P. Strugnell, S. A. Knutson, J. C. Pamidronate and 1,24(S)-dihydroxyvitamin D2 synergistically inhibit the growth of myeloma, breast and prostate cancer cells. Anticancer Res. 2005 May-Jun; 25 (3B): 1909-17.